E-LIB Suche - Ergebnisse für: Shaw, Alice T.

1

Therapy-induced APOBEC3A drives evolution of persistent can..:

Isozaki, Hideko ; Sakhtemani, Ramin ; Abbasi, Ammal...
Nature. 620 (2023) 7973 - p. 393-401 , 2023

2

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlat..:

Soo, Ross A. ; Martini, Jean-François ; van der Wekken, Anthonie J....
Journal of Thoracic Oncology. 18 (2023) 11 - p. 1568-1580 , 2023

Link: https://doi.org/10.1016/..

3

ALK-positive lung cancer: a moving target:

Schneider, Jaime L. ; Lin, Jessica J. ; Shaw, Alice T.
Nature Cancer. 4 (2023) 3 - p. 330-343 , 2023

Link: https://doi.org/10.1038/..

4

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK..:

Bearz, Alessandra ; Martini, Jean-François ; Jassem, Jacek...
Journal of Thoracic Oncology. 18 (2023) 11 - p. 1581-1593 , 2023

Link: https://doi.org/10.1016/..

5

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, U..:

Chen, Joseph ; Bearz, Alessandra ; Kim, Dong-Wan...
Clinical Pharmacokinetics. 63 (2023) 2 - p. 171-182 , 2023

Link: https://doi.org/10.1007/..

6

Plain language summary of the updated results from the CROW..:

Solomon, Benjamin J ; Bauer, Todd M ; K Mok, Tony S...
Future Oncology. 19 (2023) 14 - p. 961-973 , 2023

Link: https://doi.org/10.2217/..

7

Patient-reported outcomes from the randomized phase 3 CROWN..:

Mazieres, Julien ; Iadeluca, Laura ; Shaw, Alice T....
Lung Cancer. 174 (2022) - p. 146-156 , 2022

Link: https://doi.org/10.1016/..

8

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearran..:

Schneider, Jaime L. ; Muzikansky, Alona ; Lin, Jessica J....
JTO Clinical and Research Reports. 3 (2022) 7 - p. 100347 , 2022

Link: https://doi.org/10.1016/..

9

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Pro..:

Ou, Sai-Hong I. ; Solomon, Benjamin J. ; Shaw, Alice T....
Journal of Thoracic Oncology. 17 (2022) 4 - p. 568-577 , 2022

Link: https://doi.org/10.1016/..

10

Circulating Cell-free DNA as a Prognostic Biomarker in Pati..:

Dziadziuszko, Rafal ; Peters, Solange ; Mok, Tony...
Clinical Cancer Research. 28 (2022) 9 - p. 1800-1808 , 2022

Link: https://doi.org/10.1158/..

11

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC:..:

Ou, Sai-Hong Ignatius ; Fujiwara, Yutaka ; Shaw, Alice T....
JTO Clinical and Research Reports. 2 (2021) 1 - p. 100108 , 2021

Link: https://doi.org/10.1016/..

12

Three subtypes of lung cancer fibroblasts define distinct t..:

Hu, Haichuan ; Piotrowska, Zofia ; Hare, Patricia J....
Cancer Cell. 39 (2021) 11 - p. 1531-1547.e10 , 2021

Link: https://doi.org/10.1016/..

13

Plain Language Summary of the CROWN Study Comparing Lorlati..:

Solomon, Benjamin J ; Bauer, Todd M ; de Marinis, Filippo...
Future Oncology. 17 (2021) 34 - p. 4649-4656 , 2021

Link: https://doi.org/10.2217/..

14

A Phase 2 Study of Capmatinib in Patients With MET-Altered ..:

Dagogo-Jack, Ibiayi ; Moonsamy, Philicia ; Gainor, Justin F....
Journal of Thoracic Oncology. 16 (2021) 5 - p. 850-859 , 2021

Link: https://doi.org/10.1016/..

15

Outcomes According to ALK Status Determined by Central Immu..:

Mok, Tony ; Peters, Solange ; Camidge, D. Ross...
Journal of Thoracic Oncology. 16 (2021) 2 - p. 259-268 , 2021

Link: https://doi.org/10.1016/..